| |
|
|
| |
Alzheimer’s disease |
|
| |
|
|
| |
Title: |
Alzheimer’s disease |
|
|
|
| |
|
|
|
| |
Summary |
|
| |
|
|
| |
You are being asked to participate in this research study because you have been diagnosed with Alzheimer’s disease that is mild to moderate in severity. Alzheimer’s disease is a progressive condition that affects areas of the brain involved in memory, cognition, judgment, language and behavior.
BMS-708163 is an investigational drug that is being developed for the treatment of Alzheimer’s disease. Researchers want to find out if BMS-708163 can help people with Alzheimer’s disease.
|
|
| |
 |
|
| |
How Can You Qualify? |
|
| |
|
|
| |
The researchers at Princeton Medical Institute are seeking for men and women 50 – 90 years old inclusive and have a documented cognitive decline at least 6 month prior the first visit. Participants must to have a family member or caregiver who can attend appointments during research study. Other criteria for eligibility will be discussed with interested persons, without obligation, when calling the telephone number listed below.
|
|
| |
|
|
| |
Principal Investigator |
|
| |
|
|
| |
Jeffrey T Apter, MD, VD Dhaduk, MD
|
|
| |
|
|
| |
Contact |
|
| |
|
|
| |
Benjamin Shechet, Mark Schrier or Katie Yarosh
-
609-921-6050 Princeton
or
570-207-3945 Scranton
|
|
| |
|
|
| |
Location |
|
| |
|
|
| |
GMI Corporate/Princeton Medical Institute - Princeton, New Jersey
|
|
| |
|
|
| |
 |
|
|
